Thanks for sharing. pinch. Back in Nov '22, this 3rd Gen CAR-T was still in the lab but hopeful of being progressed into the clinic. And, here we are heading into the clinic with 3 trials investigating CDH17 and ongoing pre-clinical studies into other solid cancers expressing CDH17.
I think Dr Hua states 100% of GI NETs (Gastrointestinal Neuroendocrine Tumors) express CDH17 in his presentation. Does this suggest that CDH17 could be a target expressed on neuroendocrine cells manifesting as tumours elsewhere in the body?
https://www.pennmedicine.org/news/news-releases/2022/march/penn-developed-car-t-cells-suppress-gi-solid-tumor-cells-without-toxicity-to-healthy-tissue
https://www.pennmedicine.org/cancer/types-of-cancer/neuroendocrine-tumors/types-of-neuroendocrine-tumors/gastrointestinal-neuroendocrine-tumors
- Forums
- ASX - By Stock
- Chimeric: Media Thread
Thanks for sharing. pinch. Back in Nov '22, this 3rd Gen CAR-T...
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.39M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.1¢ | $9.959K | 474.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1322541 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 32523 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 880834 | 0.020 |
5 | 739999 | 0.019 |
6 | 348975 | 0.018 |
3 | 419425 | 0.017 |
10 | 1343217 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 808675 | 5 |
0.023 | 150000 | 1 |
0.024 | 400000 | 3 |
0.025 | 545000 | 2 |
0.026 | 255000 | 3 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |